Cambrex Corp. Rating Increased to Hold at Jefferson Research (CBM)
Cambrex Corp. (NYSE:CBM) was upgraded by equities researchers at Jefferson Research from a “sell” rating to a “hold” rating in a research report issued on Friday, AnalystRatingsNetwork.com reports.
A number of other analysts have also recently weighed in on CBM. Analysts at Zacks upgraded shares of Cambrex Corp. from a “neutral” rating to an “outperform” rating in a research note on Thursday, January 30th. They now have a $20.10 price target on the stock. Analysts at First Analysis upgraded shares of Cambrex Corp. from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 28th.
Shares of Cambrex Corp. (NYSE:CBM) traded up 0.53% on Friday, hitting $21.05. The stock had a trading volume of 133,472 shares. Cambrex Corp. has a one year low of $11.39 and a one year high of $22.24. The stock has a 50-day moving average of $18.33 and a 200-day moving average of $16.38. The company has a market cap of $638.9 million and a P/E ratio of 24.96.
Cambrex Corp. (NYSE:CBM) last issued its quarterly earnings data on Tuesday, February 11th. The company reported $0.30 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.30. The company had revenue of $103.00 million for the quarter, compared to the consensus estimate of $95.25 million. During the same quarter last year, the company posted $0.26 earnings per share. Cambrex Corp.’s revenue was up 46.3% compared to the same quarter last year. Analysts expect that Cambrex Corp. will post $1.09 EPS for the current fiscal year.
Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.